Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of apremilast in active psoriatic arthritis with psoriasis lesion
2010-019941-24Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apremilast in psoriatic arthritis (PsA) and psoriasis (3 arms), sponsored by Celgene Corporation. Primary endpoint: Primary efficacy endpoint. Started Sep 2010; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on 2010-019941-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019941-24.